Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 89 publications
Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 07, 2026
Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era.
Journal: Current oncology (Toronto, Ont.)
Published: March 31, 2026
Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.
Journal: Immunotherapy
Published: November 01, 2025
Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors.
Journal: Journal of the National Cancer Institute
Published: October 24, 2025
Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to 177Lu-DOTATATE in Neuroendocrine Tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 08, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 08, 2025
Leptomeningeal carcinomatosis presenting as catatonia.
Journal: BMJ case reports
Published: July 31, 2025
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).
Journal: ESMO open
Published: June 23, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 04, 2025
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.
Journal: Therapeutic advances in medical oncology
Published: October 09, 2024
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study.
Journal: Therapeutic advances in medical oncology
Published: October 08, 2024
Last Updated: 09/26/2026